Roivant's Lupus Drug Fails Mid-Stage Study, Program Terminated
Roivant's JAK/TYK2 inhibitor, brepocitinib, licensed from Pfizer, failed to achieve statistical significance in a Phase II lupus trial, leading to the discontinuation of its development in the condition. The high placebo rate was blamed for the drug's lack of efficacy.